An open-label dosing study to evaluate the safety and effects of a dietary plant-derived polysaccharide supplement on the N-glycosylation status of serum glycoproteins in healthy subjects

被引：0
|
作者：
A Alavi
O Fraser
E Tarelli
M Bland
J Axford
机构：
[1] The Sir Joseph Hotung Centre for Musculoskeletal Disorders,Division of Cellular and Molecular Medicine
[2] St George's University of London,Division of Bi
[3] The Biomics Centre, Medical Sciences
[4] St George's University of London,Department of Health Sciences
[5] University of York,undefined
来源：
European Journal of Clinical Nutrition | 2011年 / 65卷
关键词：
dietary plant polysaccharides; Serum glycosylation; -glycans; dietary fiber; glycomodifications; sialylation;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：648 / 656
页数：8
相关论文
共 17 条
  • [1] An open-label dosing study to evaluate the safety and effects of a dietary plant-derived polysaccharide supplement on the N-glycosylation status of serum glycoproteins in healthy subjects
    Alavi, A.
    Fraser, O.
    Tarelli, E.
    Bland, M.
    Axford, J.
    EUROPEAN JOURNAL OF CLINICAL NUTRITION, 2011, 65 (05) : 648 - 656
  • [2] A Phase 1, Open-Label Study to Evaluate the Effects of Food and Evening Dosing on the Pharmacokinetics of Oral Trofinetide in Healthy Adult Subjects
    Mona Darwish
    James M. Youakim
    Jim Harlick
    Daryl DeKarske
    Serge Stankovic
    Clinical Drug Investigation, 2022, 42 : 513 - 524
  • [3] A Phase 1, Open-Label Study to Evaluate the Effects of Food and Evening Dosing on the Pharmacokinetics of Oral Trofinetide in Healthy Adult Subjects
    Darwish, Mona
    Youakim, James M.
    Harlick, Jim
    DeKarske, Daryl
    Stankovic, Serge
    CLINICAL DRUG INVESTIGATION, 2022, 42 (06) : 513 - 524
  • [4] Clinical evaluation of DiCholTM, a dietary supplement, in healthy and diabetic patients : A Randomized open-label controlled study in human subjects
    Nag, B
    Thirucote, RR
    Nag, A
    Sriram, S
    DIABETES, 2002, 51 : A601 - A601
  • [5] Effects of Rifampicin (Rifampin) on the Pharmacokinetics and Safety of Ambrisentan in Healthy Subjects A Single-Sequence, Open-Label Study
    Harrison, Brooke
    Magee, Mindy H.
    Mandagere, Arun
    Walker, Gennyne
    Dufton, Christopher
    Henderson, Linda S.
    Boinpally, Ramesh
    CLINICAL DRUG INVESTIGATION, 2010, 30 (12) : 875 - 885
  • [6] A Phase I, Open-label, Single-Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of AMG 986 in Healthy Japanese Subjects
    Trivedi, Ashit
    Mather, Omar
    Vega, Silvia
    Hutton, Shauna
    Hellawell, Jennifer
    Lee, Edward
    DRUGS IN R&D, 2022, 22 (02) : 141 - 146
  • [7] A Phase I, Open-label, Single-Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of AMG 986 in Healthy Japanese Subjects
    Ashit Trivedi
    Omar Mather
    Silvia Vega
    Shauna Hutton
    Jennifer Hellawell
    Edward Lee
    Drugs in R&D, 2022, 22 : 141 - 146
  • [8] A Phase I Open-Label Study to Evaluate the Effects of Rifampin on the Pharmacokinetics of Olanzapine and Samidorphan Administered in Combination in Healthy Human Subjects
    Sun, Lei
    McDonnell, David
    Yu, Miao
    Kumar, Vipul
    von Moltke, Lisa
    CLINICAL DRUG INVESTIGATION, 2019, 39 (05) : 477 - 484
  • [9] A Phase I Open-Label Study to Evaluate the Effects of Rifampin on the Pharmacokinetics of Olanzapine and Samidorphan Administered in Combination in Healthy Human Subjects
    Lei Sun
    David McDonnell
    Miao Yu
    Vipul Kumar
    Lisa von Moltke
    Clinical Drug Investigation, 2019, 39 : 477 - 484
  • [10] A randomized, open-label, single-dose, two-cycle crossover study to evaluate the bioequivalence and safety of lenvatinib and Lenvima® in Chinese healthy subjects
    Xu, Zhongnan
    Wang, Yanli
    Liu, Guangwen
    Chen, Jiahui
    Wang, Wanhua
    Cheng, Yang
    Ren, Qing
    Cui, Yingzi
    Yang, Wei
    Liu, Zhengzhi
    Chen, Xuesong
    Xue, Jinling
    Chang, Tianying
    Qu, Xinyao
    Yu, Shuang
    Zhou, Yannan
    Xu, Kaibo
    Su, Zhengjie
    Deng, Qiaohuan
    Zhao, Yicheng
    Yang, Haimiao
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2022, 31 (07) : 737 - 746
12